ALLO - Cell Therapy Focused Allogene Therapeutics' Resource Prioritization A Bold Move Says Analyst | Benzinga
Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-cel (ALLO-501A) and is now pursuing a potentially pivotal trial (ALPHA3) evaluating cema-cel as a consolidation therapy in large B-cell lymphoma (LBCL) patients in the first-line setting who are minimal residual disease positive (MRD+) following R-CHOP.
Start-up activities for the trial are already underway.
Allogene will initiate a new ALPHA2 cohort of 12 patients to evaluate cema-cel in patients with chronic lymphocytic leukemia (CLL) and will leverage currently active ALPHA2 U.S. trial sites to enroll patients. Enrolment will start in Q1 2024, with initial data expected ...